Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 24 · below the Ichimoku cloud · RSI 9 (oversold) · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in NUMD in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NUMD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.8 | 7.7 | -28.1 | 52.5 | -39.2 | 13.5 | 58.9 | 25.0 | -36.5 | -43.8 | −52.5% | ||
| 2025 | -8.1 | -21.6 | 687.3 | -36.3 | -5.2 | -10.2 | 3.8 | -35.6 | -0.9 | -3.8 | -18.9 | -29.0 | +12.6% |
| 2024 | -30.2 | 31.1 | 83.8 | -4.7 | -22.8 | 48.0 | -9.7 | -17.5 | -11.5 | -50.0 | -18.9 | -22.5 | −62.1% |
| 2023 | -9.1 | -24.3 | 59.0 | -36.8 | 73.7 | -4.0 | -5.3 | 26.7 | -14.5 | -2.6 | -21.1 | 169.7 | +145.2% |
| 2022 | -15.7 | -22.0 | -4.3 | -36.4 | 0.0 | 20.7 | 83.4 | -45.2 | 61.8 | 7.1 | -22.0 | -28.1 | −52.9% |
| 2021 | -44.4 | 19.6 | -16.4 | -40.0 | -36.3 | -16.2 | -20.7 | -46.9 | 48.4 | -29.8 | -53.0 | 6.1 | −96.1% |
| 2020 | -0.0 | 0.0 | 22.2 | 27.3 | 14.3 | 18.7 | 5.3 | 5.0 | 0.0 | 0.0 | 19.0 | -28.0 | +100.0% |
| 2019 | -13.3 | 7.4 | 21.5 | -11.6 | -20.0 | 25.0 | -13.3 | -21.5 | -11.8 | 0.0 | -11.1 | 12.5 | −40.0% |
| 2018 | 0.0 | 0.0 | 50.0 | 0.0 | 33.3 | 25.0 | -1.0 | 0.0 | -8.1 | -34.1 | 41.7 | -11.8 | +87.5% |
| 2017 | -4.0 | -16.7 | 0.0 | 20.0 | -16.7 | 0.0 | 1.5 | -6.4 | 84.2 | 5.7 | -18.9 | 33.3 | +60.0% |
| 2016 | -52.1 | 0.0 | -11.1 | 10.0 | 13.6 | -30.2 | -0.3 | -13.8 | 33.3 | 12.5 | -22.2 | -28.6 | −73.4% |
| 2015 | 54.5 | 0.0 | 0.0 | 5.9 | -27.8 | 47.7 | -21.9 | -6.7 | -14.3 | -8.3 | -9.1 | 88.0 | +70.9% |
| 2014 | -30.0 | 0.0 | -21.4 | −45.0% |
No insider transactions reported for NUMD.
No analyst coverage for this instrument.
Nu-Med Plus, Inc., a medical device company, engages in the design, innovation, development, enhancement, and commercialization of medical devices worldwide. The company develops a nitric oxide generating formulation; a hospital bedside nitric oxide delivery system; a clinical unit for use in medical clinics and rehabilitation centers. It is also involved in the development of a mobile rechargeable device to deliver nitric oxide gas; and a nitric oxide system that can be used for research applications, as well as a mobile/portable rechargeable device to deliver inhaled nitric oxide gas. Nu-Med Plus, Inc. was incorporated in 2011 and is based in Port Jefferson, New York.
No recent headlines.